A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, thyroid cancer and other somatic and heritable mutations.

A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin C, vitamin E, N-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin A (palmitate), vitamin D-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, D-Biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin C, d-alpha tocopheryl acid succinate, alpha tocopherol, N-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, thyroid cancer and other somatic and heritable mutations.

The present invention relates to a composition comprising alfa-lipoic acid, or a salt or complex thereof, and honokiol, wherein the weight quantity of said honokiol is between 1% and 30% with respect to the total weight of honokiol and alfa-lipoic acid.

The present invention relates to a composition comprising alfa-lipoic acid, or a salt or complex thereof, and honokiol, wherein the weight quantity of said honokiol is between 1% and 30% with respect to the total weight of honokiol and alfa-lipoic acid.

The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or obesity, including administering a pet food composition including pyruvic acid or a salt thereof to a companion animal, or lipoic acid or salt thereof and pyruvic acid or a salt thereof to a companion animal. The invention encompasses pet food compositions and methods for managing weight including administering a pet food composition including pyruvic acid or a salt thereof, or lipoic acid or a salt thereof and pyruvic acid or a salt thereof to a companion animal to a companion animal.

The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or obesity, including administering a pet food composition including pyruvic acid or a salt thereof to a companion animal, or lipoic acid or salt thereof and pyruvic acid or a salt thereof to a companion animal. The invention encompasses pet food compositions and methods for managing weight including administering a pet food composition including pyruvic acid or a salt thereof, or lipoic acid or a salt thereof and pyruvic acid or a salt thereof to a companion animal to a companion animal.

Flavored chewable wafers containing caffeine suitable for increasing alertness and allow an individual to perform tasks in a more focused and energetic manner comprises, formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients.

Flavored chewable wafers containing caffeine suitable for increasing alertness and allow an individual to perform tasks in a more focused and energetic manner comprises, formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients.

Dietary supplements for reducing damage to brain cells characterized by loss of brain cells or loss of brain cell function in patients that have suffered from traumatic brain injury (TBI) while participating in sports and/or other athletic events are disclosed herein. The Nutraceutical compositions offer possible ameliorating effects for the secondary phase of TBI. Creatine, vitamin E, zinc, magnesium, DHA, and lipoic acid, taken together, offer a prophylactic measure to ameliorate brain damage that occurs during the secondary phase of SRTBI.

Dietary supplements for reducing damage to brain cells characterized by loss of brain cells or loss of brain cell function in patients that have suffered from traumatic brain injury (TBI) while participating in sports and/or other athletic events are disclosed herein. The Nutraceutical compositions offer possible ameliorating effects for the secondary phase of TBI. Creatine, vitamin E, zinc, magnesium, DHA, and lipoic acid, taken together, offer a prophylactic measure to ameliorate brain damage that occurs during the secondary phase of SRTBI.